GSK5784283

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaPulmonary Disease, Chronic ObstructiveNasal Polyps

175 competitors in Asthma

#DrugCompanyPhaseTrials

1

GSK5784283

GSK

Phase 3

42

Celexa

AbbVie

Preclinical

13

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

15

DUPIXENT

Regeneron

Preclinical

16

Paracetamol

GSK

Preclinical

17

Blood Withdrawn

Emergent BioSolutions

Preclinical

18

Aclidinium Bromide

AstraZeneca

Preclinical

—9

Atrovent

Boehringer Ingelheim

Preclinical

210

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1Show 16 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Asthma4 trials

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK5784283 (Felcorekibart) as an Add-On Therapy in Adults and Adolescents With Uncontrolled Asthma (PERSIST ASTHMA-2)

Not yet recruiting·GSK·Phase 3·NCT07782996·370 enrolled

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of GSK5784283 (Felcorekibart) as an Add-On Therapy in Adults and Adolescents With Uncontrolled Asthma (PERSIST ASTHMA-1)

Not yet recruiting·GSK·Phase 3·NCT07780643·514 enrolled

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Dose Finding, Parallel Group, Phase 2 Study of an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

Active, not recruiting·GSK·Phase 2·NCT06748053·307 enrolled

Show 1 more trial

Open-Label, Randomized, Single Dose, Parallel Group, Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Two Formulations of GSK5784283 Administered by Subcutaneous Injection

Recruiting·GSK·Phase 1·NCT07712393·24 enrolled

Pulmonary Disease, Chronic Obstructive2 trials

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)

Recruiting·GSK·Phase 3·NCT07780669·624 enrolled

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-2)

Not yet recruiting·GSK·Phase 3·NCT07780656·624 enrolled

Nasal Polyps2 trials

A Randomized, Double-blind, Parallel Group Phase 3 Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (PERSIST CRSwNP-1)

Not yet recruiting·GSK·Phase 3·NCT07782970·218 enrolled

A Randomized, Double-blind, Parallel Group Phase 3 Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (PERSIST CRSwNP-2)

Not yet recruiting·GSK·Phase 3·NCT07782957·218 enrolled

Details

Drug Info

Related News